PE20210373A1 - Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos - Google Patents
Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismosInfo
- Publication number
- PE20210373A1 PE20210373A1 PE2021000090A PE2021000090A PE20210373A1 PE 20210373 A1 PE20210373 A1 PE 20210373A1 PE 2021000090 A PE2021000090 A PE 2021000090A PE 2021000090 A PE2021000090 A PE 2021000090A PE 20210373 A1 PE20210373 A1 PE 20210373A1
- Authority
- PE
- Peru
- Prior art keywords
- prevent
- same
- pharmaceutical compositions
- pyrimidine compounds
- cancers including
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 abstract 2
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 abstract 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE PIRIMIDINA DE FORMULA (1) DONDE R1, R2, R3, R4, R5, R6, R7, X, Y, Z Y k SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 5-CLORO-N-(3-CICLOPROPIL-5-(((3R,5S)-3,5-DIMETILPIPERAZIN-1-IL)METIL)FENIL)-4-(6-FLUORO-1H-INDOLO-3-IL)PIRIMIDIN-2-AMINA; N-(3-CICLOPROPIL-5-(((3R,5S)-3,5-DIMETILPIPERAZIN-1-IL)METIL)FENIL)-4-(6-METIL-1H-INDOLO-3-IL)PIRIMIDIN-2-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA CINASA FLT3 SIENDO UTILES EN EL TRATAMIENTO DE LEUCEMIA MIELOIDE AGUDA, LEUCEMIA LINFOCITICA AGUDA, LEUCEMIA MIELOIDE CRONICA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180086768A KR101954370B1 (ko) | 2018-07-25 | 2018-07-25 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| PCT/KR2019/001737 WO2020022600A1 (en) | 2018-07-25 | 2019-02-13 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210373A1 true PE20210373A1 (es) | 2021-02-26 |
Family
ID=65760263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000090A PE20210373A1 (es) | 2018-07-25 | 2019-02-13 | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11292786B2 (es) |
| EP (1) | EP3810601A4 (es) |
| JP (1) | JP6806931B2 (es) |
| KR (1) | KR101954370B1 (es) |
| CN (2) | CN112469715B (es) |
| AR (1) | AR119657A1 (es) |
| BR (1) | BR112021001122A2 (es) |
| CA (1) | CA3106961A1 (es) |
| CL (1) | CL2021000175A1 (es) |
| DO (1) | DOP2021000017A (es) |
| MX (1) | MX2021000941A (es) |
| PE (1) | PE20210373A1 (es) |
| PH (1) | PH12021550124A1 (es) |
| SG (1) | SG11202100076RA (es) |
| TW (1) | TWI839363B (es) |
| WO (1) | WO2020022600A1 (es) |
| ZA (1) | ZA202100485B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20212153A1 (es) * | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda |
| US20220354842A1 (en) * | 2019-06-27 | 2022-11-10 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| WO2021066443A1 (ko) * | 2019-09-30 | 2021-04-08 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| WO2022098083A1 (ko) * | 2020-11-05 | 2022-05-12 | 한미약품 주식회사 | Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 |
| BR112023016986A2 (pt) * | 2021-02-26 | 2023-11-07 | Tyra Biosciences Inc | Compostos de aminopirimidina e métodos de seu uso |
| WO2022216097A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 스탠다임 | 신규한 lrrk2 억제제 |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| KR20230056331A (ko) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| IL313670A (en) | 2021-12-30 | 2024-08-01 | Biomea Fusion Inc | Pyrazine compounds as inhibitors of FLT3 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| EP2212293A4 (en) | 2007-10-24 | 2010-12-01 | Merck Sharp & Dohme | ANTAGONISTS OF T-TYPE CALCIUM CHANNELS BASED ON HETEROCYCLIC AMIDE |
| FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CA2767089A1 (en) * | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| MY162132A (en) * | 2010-06-23 | 2017-05-31 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| TW201219383A (en) * | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
| WO2014155300A2 (en) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| US10106526B2 (en) * | 2014-04-04 | 2018-10-23 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2018002217A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as nik inhibitors |
| HUE056472T2 (hu) * | 2017-01-26 | 2022-02-28 | Hanmi Pharm Ind Co Ltd | Pirimidin vegyület és annak gyógyszerészeti felhasználása |
-
2018
- 2018-07-25 KR KR1020180086768A patent/KR101954370B1/ko active IP Right Grant
-
2019
- 2019-02-13 MX MX2021000941A patent/MX2021000941A/es unknown
- 2019-02-13 JP JP2019566602A patent/JP6806931B2/ja active Active
- 2019-02-13 EP EP19841611.7A patent/EP3810601A4/en active Pending
- 2019-02-13 CN CN201980049569.8A patent/CN112469715B/zh active Active
- 2019-02-13 CN CN202310204523.7A patent/CN116693506A/zh active Pending
- 2019-02-13 SG SG11202100076RA patent/SG11202100076RA/en unknown
- 2019-02-13 BR BR112021001122-6A patent/BR112021001122A2/pt unknown
- 2019-02-13 PE PE2021000090A patent/PE20210373A1/es unknown
- 2019-02-13 CA CA3106961A patent/CA3106961A1/en active Pending
- 2019-02-13 WO PCT/KR2019/001737 patent/WO2020022600A1/en active Application Filing
- 2019-07-09 TW TW108124118A patent/TWI839363B/zh active
- 2019-07-24 AR ARP190102087A patent/AR119657A1/es unknown
-
2020
- 2020-04-27 US US16/859,413 patent/US11292786B2/en active Active
-
2021
- 2021-01-15 PH PH12021550124A patent/PH12021550124A1/en unknown
- 2021-01-22 CL CL2021000175A patent/CL2021000175A1/es unknown
- 2021-01-22 ZA ZA2021/00485A patent/ZA202100485B/en unknown
- 2021-01-22 DO DO2021000017A patent/DOP2021000017A/es unknown
-
2022
- 2022-01-25 US US17/583,841 patent/US20230002358A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3810601A4 (en) | 2022-04-20 |
| ZA202100485B (en) | 2023-11-29 |
| WO2020022600A1 (en) | 2020-01-30 |
| CN112469715A (zh) | 2021-03-09 |
| SG11202100076RA (en) | 2021-02-25 |
| PH12021550124A1 (en) | 2021-09-27 |
| KR101954370B1 (ko) | 2019-03-05 |
| JP2020527128A (ja) | 2020-09-03 |
| US20230002358A1 (en) | 2023-01-05 |
| US20200255410A1 (en) | 2020-08-13 |
| EP3810601A1 (en) | 2021-04-28 |
| JP6806931B2 (ja) | 2021-01-06 |
| CA3106961A1 (en) | 2020-01-30 |
| AR119657A1 (es) | 2022-01-05 |
| CL2021000175A1 (es) | 2021-07-02 |
| DOP2021000017A (es) | 2021-04-15 |
| US11292786B2 (en) | 2022-04-05 |
| BR112021001122A2 (pt) | 2021-04-13 |
| CN116693506A (zh) | 2023-09-05 |
| CN112469715B (zh) | 2024-06-11 |
| MX2021000941A (es) | 2021-03-09 |
| TWI839363B (zh) | 2024-04-21 |
| TW202014417A (zh) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20210642A1 (es) | Inhibidores de pd-1/pd-l1 | |
| PE20220569A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos | |
| PE20201202A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20210004A1 (es) | Inhibidores de mcl-1 | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| PE20200177A1 (es) | Inhibidores de pd-1/pd-l1 | |
| PE20050462A1 (es) | COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5) | |
| PE20151274A1 (es) | Inhibidores de erk y sus usos | |
| PE20161073A1 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| PE20090772A1 (es) | Derivados de bencimidazol | |
| PE20161443A1 (es) | Compuestos | |
| PE20120798A1 (es) | Potentes inhibidores de molecula pequena de autofagia | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
| PE20131377A1 (es) | Triazina-oxadiazoles | |
| PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| PE20140626A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| PE20081447A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| PE20110367A1 (es) | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 | |
| UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |